Elevar Therapeutics
Latest, September 23, 2026FDA approved Lyrfigtu (lirafugratinib) on September 23, 2026 for previously treated FGFR2 fusion cholangiocarcinoma, Elevar's first approved drug. The FDA declined to approve rivoceranib with camrelizumab for liver cancer in July 2026, and Elevar plans to resubmit. Lyrfigtu drug page with FDA sources
Elevar Therapeutics works on 1 rare disease tracked on Trial Friend, including Cholangiocarcinoma, with 1 recruiting clinical trial and 1 FDA-approved rare disease drug.
Elevar Therapeutics is a Fort Lee, New Jersey biopharmaceutical company (formerly LSK BioPharma) and a majority-owned subsidiary of South Korea's HLB Group. Its lead programs are lirafugratinib, a selective FGFR2 inhibitor licensed globally from Relay Therapeutics in December 2024 for FGFR2 fusion-driven cholangiocarcinoma, approved by the FDA as Lyrfigtu on September 23, 2026, and rivoceranib, a VEGFR-2 inhibitor developed with camrelizumab for first-line hepatocellular carcinoma. The FDA declined to approve that combination in July 2026 because of problems found at a manufacturing site inspection, and Elevar says it is preparing to resubmit.
Elevar Therapeutics Drug Pipeline
Elevar Therapeutics has 1 active clinical trial across 1 development stage, with 1 currently recruiting participants. Clinical trials advance through phases: Phase 1 tests safety in a small group, Phase 2 evaluates effectiveness and side effects, Phase 3 confirms benefit in a larger population, and Phase 4 monitors long-term safety after FDA approval.
Note: This pipeline counts the active and recruiting trials listed on this page, from ClinicalTrials.gov. For companies that work outside rare disease, we list only trials for rare diseases we track, so the company's full pipeline may be larger.
Elevar Therapeutics Clinical Trials (1)
Active and recruiting clinical trials sponsored by Elevar Therapeutics, sourced live from ClinicalTrials.gov. Each trial card shows the study phase, current recruitment status, conditions under investigation, study locations, eligibility criteria, and a direct link to the full ClinicalTrials.gov record. You can also download a one-page PDF summary to share with your doctor.
Note: Recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator.
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only Elevar Therapeutics. Unsubscribe anytime.
You'll get new recruiting trials, changes to trials, FDA decisions and condition news for Cholangiocarcinoma. Turn any of these off from the link in every email.
Elevar Therapeutics FDA-Approved Drugs (1)
Medications developed or marketed by Elevar Therapeutics that have received U.S. Food and Drug Administration approval. Drug data is sourced from the openFDA database and includes brand names, generic names, approval dates, and matched rare disease indications. Where a drug treats a condition covered by Trial Friend, the disease name links directly to that disease page.
| Drug Name | Brand Name | Rare Diseases | Approval Date |
|---|---|---|---|
| LIRAFUGRATINIB | LYRFIGTU | Sep 23, 2026 |
Elevar Therapeutics Trial Locations
Elevar Therapeutics clinical trials are running at 19 sites in 5 countries. Click any country to drill down by state, city, and individual research facility. Proximity to a trial site is one of the most important factors in deciding whether to participate.
Rare Disease Focus Areas (1)
Diseases targeted by Elevar Therapeutics's clinical trial and drug development programs
Patient Resources
Organizations and resources related to Elevar Therapeutics's rare disease focus areas
Frequently Asked Questions About Elevar Therapeutics
Common questions about Elevar Therapeutics's rare disease programs, clinical trials, and treatments.